Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

TRIB US Equity

Trinity Biotech PLCHealth Care · In Vitro & In Vivo Diagnostic Substances · CIK 888721 · FY ends Dec 31
$12.43
+1.26 (+11.28%)
USD · as of 2026-08-18 · marketstack
2 registered studies · 0 active

Studies where TRIB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

2 observational

Held by 1 tracked-famous manager (SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusConditionsEnrollmentPrimary completionUpdated
Clinical Study to Validate the Use of a New Point of Care Troponin I TestNCT02620397observationalClinical performance of the Meritas Troponin I testUnknown statusAcute Coronary Syndrome1,500Oct 2015actual2015-12-15
99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I TestNCT02638311observational99th percentile for Troponin results determined from whole blood and plasma in apparetly healthy volunteer populationCompletedAcute Coronary Syndrome769Jul 2015actual2015-12-23

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19